|
|
ASH 2011: Dr. Richardson - Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study
Paul G. Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
|
|
|
Be the first to comment